GW&K Investment Management LLC Trims Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• GW&K Investment Management reduced its stake in IDEXX by 16.1% in the third quarter, selling 5,572 shares and leaving 29,109 shares valued at about $18.6 million.
• Insiders have sold heavily: a total of 45,957 shares (~$29.86 million) were sold last quarter, including EVP George Fennell (11,345 shares) and CEO Jonathan Mazelsky (23,326 shares).
• Analysts have trimmed targets recently but the consensus remains a Moderate Buy with an average target of $783.33; the stock trades near $619 with a P/E of 47.35 and FY2026 EPS guidance of 14.29–14.80.

GW&K Investment Management LLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 16.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,109 shares of the company's stock after selling 5,572 shares during the quarter. GW&K Investment Management LLC's holdings in IDEXX Laboratories were worth $18,597,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in IDXX. Empowered Funds LLC grew its stake in IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company's stock worth $646,000 after acquiring an additional 95 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $265,000. Huntington National Bank grew its stake in IDEXX Laboratories by 0.5% in the second quarter. Huntington National Bank now owns 3,651 shares of the company's stock worth $1,958,000 after purchasing an additional 19 shares in the last quarter. NewSquare Capital LLC increased its holdings in IDEXX Laboratories by 87.5% during the 2nd quarter. NewSquare Capital LLC now owns 75 shares of the company's stock worth $40,000 after purchasing an additional 35 shares during the period. Finally, Crestwood Advisors Group LLC raised its position in IDEXX Laboratories by 3.7% during the 2nd quarter. Crestwood Advisors Group LLC now owns 860 shares of the company's stock valued at $461,000 after purchasing an additional 31 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on IDXX shares. UBS Group dropped their price target on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 3rd. Barclays cut their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Piper Sandler lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a report on Monday, February 9th. Weiss Ratings cut IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, January 29th. Finally, Wall Street Zen lowered IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $783.33.

Insider Activity

In other news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares of the company's stock, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Trading Down 4.6%

NASDAQ:IDXX opened at $618.92 on Friday. The stock has a market capitalization of $49.28 billion, a price-to-earnings ratio of 47.35, a PEG ratio of 3.94 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The firm has a 50 day moving average of $668.54 and a 200 day moving average of $668.40.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.07 billion. During the same quarter in the prior year, the company posted $2.53 EPS. The business's revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.